Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies

Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies

Abstract The need for high-affinity, SARS-CoV-2-specific monoclonal antibodies (mAbs) is critical in the face of the global COVID-19 pandemic, as such reagents can have important diagnostic, research, and therapeutic applications. Of greatest interest is the ~ 300 amino acid receptor binding domain...

Full description

Bibliographic Details
Main Authors: Asheley P. Chapman, Xiaoling Tang, Joo R. Lee, Asiya Chida, Kristina Mercer, Rebekah E. Wharton, Markus Kainulainen, Jennifer L. Harcourt, Roosecelis B. Martines, Michelle Schroeder, Liangjun Zhao, Anton Bryksin, Bin Zhou, Eric Bergeron, Brigid C. Bollweg, Azaibi Tamin, Natalie Thornburg, David E. Wentworth, David Petway, Dennis A. Bagarozzi, M. G. Finn, Jason M. Goldstein
Format: Article
Language:English
Published: Nature Portfolio 2021-05-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-88809-0

Internet

https://doi.org/10.1038/s41598-021-88809-0

Similar Items